Bissinger R, Bhuyan AAM, Qadri SM, Lang F
#FDA #Generics #PublicHealth #DrugDevelopment #ANDA #PSG #Pharma To view or add a comment, sign in Novo Nordisk has received CDSCO approval for its blockbuster drug Ozempic, completing its semaglutide portfolio in India as the obesity-treatment market expands rapidly Sanket Koul reports #NovoNordisk #Ozempic #Obesity #WeightLoss #Pharma To view or add a comment, sign in BREAKING NEWS - FDA approves the first new treatment for idiopathic pulmonary fibrosis in over a decade Boehringer Ingelheims JASCAYD (nerandomilast) has just received FDA approval as the first new therapy for idiopathic pulmonary fibrosis (IPF) in more than 10 years
The most common user-reported experience: Temporary skin dryness in week 1 (resolves by week 2) Occasional injection site redness (standard for any subQ peptide) Some users report increased hair growth, including in unintended areas at higher doses At doses above 34 mg/day, some protocols note headaches, but this is well above standard dosing
Resta-Lenert S, Barrett KE: Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells
If youve looked into GLP-1 therapy for weight loss, youve almost certainly run into both semaglutide and tirzepatide